Recurrent Respiratory Papillomatosis
Respiratory·MeSH: Recurrent respiratory papillomatosis
Prevalence
5.0 / 100K
9 drugs in development·1 company·3 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| papzimeos | PRECIGEN, INC. (PGEN) |
Phase 2(2)
Phase 1(5)
Phase 4(1)
| Drug | Company |
|---|---|
| Zopapogene imadenovec | PRECIGEN, INC. (PGEN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Recurrent Respiratory Papillomatosis?
BioSniper tracks 9 drugs in development for Recurrent Respiratory Papillomatosis across 1 company.
How many clinical trials target Recurrent Respiratory Papillomatosis?
There are 3 clinical trials targeting Recurrent Respiratory Papillomatosis tracked by BioSniper.
What is the prevalence of Recurrent Respiratory Papillomatosis?
The estimated prevalence of Recurrent Respiratory Papillomatosis is approximately 5.0 per 100,000 population.
Deep-dive into Recurrent Respiratory Papillomatosis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis